Biological mechanisms of bevacizumab-associated adverse events

Area of Science:

• Oncology
• Vascular Biology
• Pharmacology

Background:

• Cancer-associated angiogenesis relies on distinct endothelial cell cycle activity compared to normal cells.
• Targeting tumor vasculature offers potential benefits including overcoming resistance and reducing normal tissue toxicity.
• Bevacizumab, an anti-angiogenic agent, was approved for metastatic colorectal cancer and later for lung, breast, and glioblastoma.

Purpose of the Study:

• To review the relationship between vascular endothelial growth factor (VEGF) inhibition and observed toxicities.
• To propose pathogenic mechanisms underlying adverse events associated with anti-angiogenic therapy.

Main Methods:

• Literature review of clinical trials and preclinical studies on anti-angiogenic agents.
• Analysis of reported toxicities associated with VEGF inhibition.
• Pathophysiological assessment of mechanisms linking VEGF inhibition to adverse events.

Main Results:

• Anti-angiogenic therapy, exemplified by bevacizumab, has demonstrated clinical efficacy across multiple cancer types.
• Despite benefits, significant soft-tissue and vascular toxicities are associated with bevacizumab treatment.
• VEGF inhibition is implicated in the development of these adverse events.

Conclusions:

• While anti-angiogenic therapy is a valuable tool in oncology, understanding and mitigating its associated toxicities is crucial.
• Further research into the pathogenic mechanisms of VEGF inhibition-related adverse events is warranted.
• Strategies to manage or prevent these toxicities may improve patient outcomes and expand the therapeutic window for anti-angiogenic agents.